A detailed history of Black Rock Inc. transactions in Biodesix Inc stock. As of the latest transaction made, Black Rock Inc. holds 415,908 shares of BDSX stock, worth $573,953. This represents 0.0% of its overall portfolio holdings.

Number of Shares
415,908
Previous 402,908 3.23%
Holding current value
$573,953
Previous $576,000 10.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.21 - $1.71 $15,730 - $22,230
13,000 Added 3.23%
415,908 $636,000
Q1 2024

May 10, 2024

SELL
$1.35 - $2.12 $2,096 - $3,292
-1,553 Reduced 0.38%
402,908 $576,000
Q4 2023

Feb 13, 2024

BUY
$1.2 - $2.13 $4,966 - $8,816
4,139 Added 1.03%
404,461 $744,000
Q3 2023

Nov 13, 2023

SELL
$1.04 - $1.74 $9,481 - $15,863
-9,117 Reduced 2.23%
400,322 $660,000
Q2 2023

Aug 11, 2023

BUY
$1.12 - $1.88 $10,524 - $17,666
9,397 Added 2.35%
409,439 $503,000
Q1 2023

May 12, 2023

BUY
$1.52 - $2.5 $547,069 - $899,785
359,914 Added 896.91%
400,042 $744,000
Q4 2022

Feb 13, 2023

BUY
$0.98 - $2.3 $815 - $1,913
832 Added 2.12%
40,128 $92,000
Q3 2022

Nov 14, 2022

BUY
$1.24 - $2.89 $2,548 - $5,938
2,055 Added 5.52%
39,296 $50,000
Q2 2022

Aug 12, 2022

SELL
$1.32 - $2.12 $702,709 - $1.13 Million
-532,356 Reduced 93.46%
37,241 $61,000
Q1 2022

May 12, 2022

SELL
$1.69 - $5.81 $12,920 - $44,417
-7,645 Reduced 1.32%
569,597 $962,000
Q4 2021

Feb 10, 2022

BUY
$4.09 - $8.67 $24,826 - $52,626
6,070 Added 1.06%
577,242 $3.05 Million
Q3 2021

Nov 09, 2021

SELL
$6.6 - $12.78 $16,909 - $32,742
-2,562 Reduced 0.45%
571,172 $4.7 Million
Q2 2021

Aug 11, 2021

BUY
$12.14 - $20.35 $6.97 Million - $11.7 Million
573,734 New
573,734 $7.58 Million

Others Institutions Holding BDSX

About BIODESIX INC


  • Ticker BDSX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 39,982,000
  • Market Cap $55.2M
  • Description
  • Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...
More about BDSX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.